De patienter, som skiftede respons efter behandling med Zevalin fra PR til CR, havde en signifikant længere median progressionsfri overlevelse (986 dage)
Patients whose response status changed after Zevalin from PR to CR showed a significantly longer median progression free survival time (986 days) compared to those patients who remained in PR (median progression free survival time of 460 days, p=0.0004).